Molecular Basis of Nucleobase Transport Systems in Mammals

Abstract

Nucleobases are water-soluble compounds that need specific transporters to cross biological membranes. Cumulative evidence based on studies using animal tissues and cells indicates that the carrier-mediated transport systems for purine and pyrimidine nucleobases can be classified into the following two types: concentrative transport systems that mediate nucleobase transport depending on the sodium ion concentration gradient; and other systems that mediate facilitated diffusion depending on the concentration gradient of the substrate. Recently, several molecular transporters that are involved in both transport systems have been identified. The function and activity of these transporters could be of pharmacological significance considering the roles that they play not only in nucleotide synthesis and metabolism but also in the pharmacokinetics and delivery of a variety of nucleobase analogues used in anticancer and antiviral drug therapy. The present review provides an overview of the recent advances in our understanding of the molecular basis of nucleobase transport systems, focusing on the transporters that mediate purine nucleobases, and discusses the involvement of intracellular metabolism in purine nucleobase transport and chemotherapy using ganciclovir.Key words purine nucleobase; transporter; salvage enzyme; equilibrative nucleoside transporter 1 (ENT1)/ solute carrier (SLC)29A1; ENT2/SLC29A2; equilibrative nucleobase transporter 1 (ENBT1)/ SLC43A3

Determinants of nutrient limitation in cancer

“…Cell surface transporters: Most nutrients are transported into cells through transmembrane proteins, and transport can be either equilibrative or coupled to an energy consuming process to concentrate the nutrient in cells (Glatz et al 2010;Hediger et al 2013;Szablewski 2013;Perez-Escuredo et al 2016;Young 2016;Inoue 2017). Many nutrient transport proteins are upregulated in cancer, and there has been a renewed interest in understanding nutrient transport phenomena in cancer (Nicklin et al 2009;Cesar-Razquin et al 2015;Krall et al 2016;Broer A et al 2018;Cha et al 2018;Ladanyi et al 2018;Tajan et al 2018;Todenhofer et al 2018).…”

Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine

“…[ 60 ] Importantly, its expression was found to localize to microvasculature endothelium such as that present in brain microvessels. [ 61 , 62 ] Therefore, SLC43A3 may be responsible for the down-gradient transport of Hyp from blood to CSF that was observed in Jimenez et al…”

A2B Adenosine Receptors: When Outsiders May Become an Attractive Target to Treat Brain Ischemia or Demyelination

“…A vesicular mechanism of adenosine release in an excitation–secretion manner has also been postulated [ 3 , 4 ]. Extracellular adenosine is removed by enzymes devoted to its degradation, such as adenosine deaminase (ADA) or adenosine kinase (AK) [ 5 ], or taken up by the equilibrative nucleoside transporter (ENT) isoforms ENT1 and ENT2 [ 6 ]. Enhanced extracellular concentrations of adenosine can be considered as a general harm signal, contributing to the recruitment of damage-associated molecular effectors [ 2 ].…”